Topics

Teva Turnaround Hung Up By The Uncertain Cost Of Settling Opioid Cases

12:09 EST 7 Nov 2019 | SCRIP

Teva's business appears to be stabilizing but the company needs to resolve outstanding opioid liability litigation. CEO Schultz said he...

      

Related Stories

 

Original Article: Teva Turnaround Hung Up By The Uncertain Cost Of Settling Opioid Cases

NEXT ARTICLE

More From BioPortfolio on "Teva Turnaround Hung Up By The Uncertain Cost Of Settling Opioid Cases"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...